RICHMOND, Va. & BUDE, England--(BUSINESS WIRE)--Tripos Discovery Research Limited (TDR), a wholly owned subsidiary of Commonwealth Biotechnologies, Inc. (CBI) group of companies (NASDAQ Capital Market:CBTE) and a leading provider of drug discovery chemistry services and small molecule products, announces today that it has entered into a service agreement with Schering-Plough Corporation (NYSE:SGP) to design, synthesize and purify high-quality, drug-like compounds to expand the compound file collection of Schering-Plough Research Institute (SPRI), the company’s research and development arm.
